Company Overview and News

 
Kinder Morgan's (KMI) CEO Steven Kean on Q1 2018 Results - Earnings Call Transcript

2018-04-19 seekingalpha
Welcome to the Quarterly Earnings Conference Call. [Operator Instructions] I would like to inform all parties that today's conference is being recorded. If you have any objections, you may disconnect at this time.
Upvote Downvote

 
Andeavor Wins A Hardship Waiver From The EPA

2018-04-05 seekingalpha
The share price of refiner Andeavor jumped to a 2-month high following news that some of its refineries have been granted "hardship exemptions" from the national biofuels mandate.
Upvote Downvote

 
Wonder how the Oil Patch impacts the world economy? Dallas Fed is trying to find out | Energy | Dallas News

2018-03-14 dallasnews
Texas oil and gas drillers aren't the only ones scrambling to dominate the energy market. The Federal Reserve Bank of Dallas continues to carve out its niche as the energy Fed.
Upvote Downvote

 
What Andeavor’s Cash Flow Analysis Reveals

2018-03-06 editors.aws.marketrealist
In 2017, Andeavor (ANDV) generated $1.6 billion in cash from operations. It had cash outflows of $2.5 billion in the form of capital expenditure and acquisitions and $314 million in the form of dividends. The acquisition outflow was primarily related to the Western Refining acquisition and the North Dakota Gathering and Processing Assets acquisition.
Upvote Downvote

 
Is Andeavor’s Debt Position Improving?

2018-03-06 editors.aws.marketrealist
Andeavor’s total debt-to-capital ratio was 36% in 4Q17. That was above the industry average of 35%. The industry average considers seven American refining companies. The debt-to-capital ratio shows the percentage of debt in a company’s capital structure ratio.
Upvote Downvote

 
Analyst Ratings for Andeavor: Why Are They Still Favorable?

2018-03-06 editors.aws.marketrealist
The analyst rating graph below shows that 17 (or 81%) of the 21 analysts covering Andeavor (ANDV) have rated it a “buy” in March 2018. Four analysts have rated it a “hold.” ANDV’s mean price target of $138 per share implies a 54% rise from its current level.
Upvote Downvote

1
CVR Refining: Hedging The Crack And The RFS

2018-02-28 seekingalpha
CVR Refining hedges its refining margins in an attempt to lock in distributions for its partners.
Upvote Downvote

 
Understanding Refining Stocks’ Moving Averages in 1Q18

2018-02-23 editors.aws.marketrealist
In 1Q17, Marathon Petroleum (MPC), Valero Energy (VLO), Andeavor (ANDV), and Phillips 66 (PSX) witnessed a decline in their stock prices. MPC, ANDV, and VLO’s 50-day moving averages remained above their 200-day moving averages. But PSX’s 50-day moving average fell below its 200-day moving average in March 2017.
Upvote Downvote

 
Did Andeavor’s Refining Margin Contract in 4Q17?

2018-02-20 editors.aws.marketrealist
Andeavor (ANDV) saw a gross refining margin contraction of $1.8 per barrel YoY (year-over-year) to $7.6 per barrel in 4Q17. Its operating costs fell $0.1 per barrel YoY to $5.3 per barrel in 4Q17.
Upvote Downvote

 
Andeavor’s 4Q17 Earnings Beat Estimates

2018-02-20 editors.aws.marketrealist
Andeavor (ANDV) posted its 4Q17 results on February 15, 2018, reporting revenue of $10.6 billion and missing Wall Street analysts’ consensus estimate.
Upvote Downvote

 
Andeavor (ANDV) Q4 Earnings, Revenues Miss Estimates

2018-02-16 zacks
Andeavor (ANDV - Free Report) reported fourth-quarter 2017 adjusted earnings from continuing operations of 37 cents per share, which missed the Zacks Consensus Estimate of $1.18. Tepid performance from the Refining segment and increased expenses led to weaker-than-expected results. The bottom line, however, improved significantly from the year-ago quarter’s loss of 2 cents per share on strong performance from the Logistics and Marketing segments.
Upvote Downvote

 
What's in Store for Andeavor (ANDV) This Earnings Season?

2018-02-12 zacks
Andeavor (ANDV - Free Report) is set to release fourth-quarter 2017 results after the closing bell on Feb 15. San Antonio, TX-based downstream operator— whose peers includes Marathon Petroleum (MPC - Free Report) , Valero Energy (VLO - Free Report) and Phillips 66 among others — reported a negative earnings surprise of 10.89% in the preceding quarter amid high costs along with lower retail and branded fuel margins.
Upvote Downvote

 
Andeavor’s 4Q17 Estimates: Could Its Earnings Surge?

2018-02-08 editors.aws.marketrealist
Andeavor (ANDV) is expected to post its 4Q17 results on February 15, 2018. Before we study its 4Q17 estimates, let’s recap ANDV’s 3Q17 performance versus the estimates.
Upvote Downvote

 
Realty Income's Yield Has Entered Buy Territory

2018-01-22 seekingalpha
Based on the current market logic for selling, the monthly dividend company is starting to become attractive.
Upvote Downvote

 
Andeavor Boosts Permian Foothold With Rangeland II Buyout

2018-01-04 zacks
In a bid to bolster its foothold in the Permian play, Andeavor (ANDV - Free Report) recently acquired Rangeland Energy II, LLC. Financial details of the transaction have been kept under wraps.  Subject to satisfactory closing conditions and regulatory approvals, the deal is set for closure by March this year.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 959319104